THC or Compazine® for the cancer chemotherapy patient—the UCLA study

Ungerleider, J. Thomas; Sarna, G; Fairbanks, Lynn A.; Goodnight, James E.; Andrysiak, Therese; Jamison, Kay Redfield

doi:10.1097/00000421-198504000-00006

Cited by 21 publications

(33 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In 14 active controlled crossover trials 3% to 46% of patients preferred the standard antiemetic. 32-34 38-40 42 44 46 51-54 59 The difference in favour of cannabinoids was significant (table 2). A subgroup analysis, taking into account history of cannabis use, was not possible since this was inconsistently reported.…”

Section: Resultsmentioning

confidence: 96%

Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic

Tramèr

Carroll²,

Campbell³

et al. 2001

BMJ

515

264

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 96%

Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic

Tramèr

Carroll²,

Campbell³

et al. 2001

BMJ

515

264

View full text Add to dashboard Cite

show abstract

“…The first product, licensed in 1981, nabilone (Cesamet ® ), a synthetic derivative of ∆ 9 -THC, is prescribed to reduce nausea and vomiting associated with cancer chemotherapy (52). In 1985, ∆ 9 -THC, marketed as dronabinol (Marinol ® ), was approved as an antiemetic for use in similar situations (53), and in 1992 was additionally marketed to stimulate appetite in conditions associated with excessive weight loss such as that occurring in AIDS (54). The newest clinically available cannabinoid, Sativex ® , is an equal mixture of ∆ 9 -THC and a plant-derived cannabinoid lacking psychotropic effects known as cannabidiol (55).…”

Section: Current Licensed Therapeutic Uses Of ∆ 9 -Thc and Other Cb1rmentioning

confidence: 99%

Marijuana-based Drugs: Innovative Therapeutics or Designer Drugs of Abuse?

Seely

Prather²,

James³

et al. 2011

Molecular Interventions

114

101

View full text Add to dashboard Cite

The principal psychoactive component of marijuana, Δ(9)-tetrahydrocannabinol (THC), activates CB1 cannabinoid receptors (CB1Rs). Unfortunately, pharmacological research into the design of effective THC analogs has been hampered by psychiatric side effects. THC-based drug design of a less academic nature, however, has led to the marketing of "synthetic marijuana," labeled as K2 or "Spice," among other terms, which elicits psychotropic actions via CB1R activation. Because of structural dissimilarity to THC, the active ingredients of K2/Spice preparations are widely unregulated. The K2/Spice "phenomenon" provides a context for considering whether marijuana-based drugs will truly provide innovative therapeutics or merely perpetuate drug abuse.

show abstract

“…On the other hand, it was observed that 2 uncontrolled case reports presented with intervention of Phytocannabis (Delta-9-THC) led to reduction in nausea and vomiting that was induced by chemotherapy and radiotherapy treatments [40][41][42][43][44][45][46][47][48][49][50][51][52][53][54]. It was also found that due to this intervention there was marked improvement in appetite and pain [40][41][42][43][44][45][46][47][48][49][50][51][52][53][54].…”

Section: Discussionmentioning

confidence: 99%

Phytocannabis for the treatment of cancer-related or cancer treatment related symptoms: Evidence Based Review

Gupta¹

2016

TIJCR

View full text Add to dashboard Cite

Cancer is defined as a generic term for a large group of diseases that was observed to affect any part of the body, often characterized by abnormal rapid growth of abnormal cells. According to WHO report, Cancer was the leading cause of morbidity and mortality worldwide. The primary goal of the treatment is to cure cancer or to considerably prolong life, along with improved patient's quality of life by palliative care, psychological support and alternative treatments. The present report focused on the use of Phytocannabis and its derivatives to alleviate the symptoms occurred due to cancer that included reduced appetite, chemotherapy-induced nausea and vomiting, radiotherapy-induced pain, nausea and vomiting in order to attenuate the disease process. Cancer, Chemotherapy and Radiotherapyinduced emesis and pain, all these mentioned factors led to the interrogation and investigation of the anti-emesis, pain relief, and mood stabilizing properties of Phytocannabis. This study presented the update on health and social consequences of Phytocannabis use, with a focus on the long-term and frequent use of medicinal Cannabis and its derivatives in alleviating the cancer related symptoms. It aimed to present the current knowledge on the impact of Phytocannabis use on health, from its impact on treating cancer related symptoms to its role in chemotherapy and Radiotherapy induced symptoms. This report evaluated the evidence on whether long-term Phytocannabis use is a contributory cause of the following health outcomes: relief from pain, nausea, vomiting, appetite, food taste, night sweats, and adverse physical and mental health effects such as mood swings, fatigue, hallucinations, postural hypotension, dizziness, mind alertness. Thus, the present paper Abbreviations THC = Tetrahydrocannabinol WHO = World Health Organization CBD = Cannabinoid CBM = Cannabis based medicine CBN = Cannabinol

show abstract

THC or Compazine® for the cancer chemotherapy patient—the UCLA study

Cited by 21 publications

References 0 publications

Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic

Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic

Marijuana-based Drugs: Innovative Therapeutics or Designer Drugs of Abuse?

Phytocannabis for the treatment of cancer-related or cancer treatment related symptoms: Evidence Based Review

Contact Info

Product

Resources

About